Skip to main content
. 2024 Aug 22;10:76. doi: 10.1038/s41523-024-00684-w

Fig. 4. Progression-free survival based on investigator assessment (subgroup analysis).

Fig. 4

a Progression-free survival in pre/perimenopausal patients. b Progression-free survival in postmenopausal patients. c Progression-free survival in patients treated with first-line endocrine therapy. d Progression-free survival in patients treated with second-line endocrine therapy. The tick marks indicate censored data. CI confidence interval; HR hazard ratio; NE not estimable; PFS progression-free survival.